Appointment dossier — Prostate Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Genistein — Review evidence · 1 positive · PMID 42133114
- Relacorilant — Review evidence · 1 positive · PMID 42334771
- Carboplatin — Review evidence · 0 positive · PMID 37485216
- Durvalumab — Review evidence · 0 positive · PMID 37485216
- Etoposide — Review evidence · 0 positive · PMID 37485216
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06945315 · Phase 3 — SAFE Nerve Sparing Guided by Micro-ultrasound (MUS) (United States)
- NCT06592924 · Phase 3 — Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (United States)
- NCT03851640 · Phase 3 — A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). (China)
- NCT07365995 · Phase 3 — A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (United States)
- NCT04700332 · Phase 2 — PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer (United States)
- NCT05616650 · Phase 2 — Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor (United States)
- NCT06155084 · Phase 1 / Phase 2 — A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients (China)
- NCT07198633 · Phase 1 / Phase 2 — A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (China)
- NCT06343038 · Phase 1 — Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (Switzerland)
- NCT06545942 · Phase 1 — Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (United States)
- NCT07705334 · Phase 1 — A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors (United States)
- NCT05549024 · Early Phase 1 — 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients (China)
- NCT04228211 — Utrecht Prostate Cohort for Cancer Treatment Intervention Studies and Long-term Evaluation (Netherlands)
- NCT05438563 — MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer (United States)
- NCT05100121 — To Live Better After Prostate Cancer Treatment: (Sweden)
- NCT05767307 — Danish Prostate Cancer Consortium Study-1 (Denmark)
- NCT06360523 — To Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial Intelligence (Hong Kong)
- NCT06636747 — High Resolution Diffusion Weighted Imaging in Prostate (China)
Most-relevant first: trials that name Prostate Cancer, then broader trials you may still qualify for. 1215 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06945315), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?